Effective omalizumab interval prolongation in the treatment of chronic urticaria

J Allergy Clin Immunol Pract. 2020 Nov-Dec;8(10):3667-3668.e1. doi: 10.1016/j.jaip.2020.06.056. Epub 2020 Jul 14.

Authors

Mehran Alizadeh Aghdam¹, Rianne Henriëtte Pieterse², Petra Adriana Kentie², Feiko Rijken², André Cornelis Knulst², Heike Röckmann²

Affiliations

¹ Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. Electronic address: [email protected].
² Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

PMID: 32679351
DOI: 10.1016/j.jaip.2020.06.056

No abstract available

MeSH terms

Anti-Allergic Agents* / therapeutic use
Chronic Disease
Chronic Urticaria*
Humans
Omalizumab / therapeutic use
Treatment Outcome
Urticaria* / drug therapy

Substances

Anti-Allergic Agents
Omalizumab